Published in Leukemia on July 23, 2009
New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia (2013) 2.04
Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Blood (2013) 1.89
Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica (2013) 1.76
Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data. Oncologist (2013) 1.70
A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. Blood (2014) 1.47
Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma. Blood Cancer J (2014) 1.30
Secondary primary malignancies in multiple myeloma: an old NEMESIS revisited. Adv Hematol (2012) 1.24
Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant (2014) 1.21
Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma. Haematologica (2010) 1.18
Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications. Leukemia (2013) 1.05
Current multiple myeloma treatment strategies with novel agents: a European perspective. Oncologist (2010) 1.04
Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma. Haematologica (2013) 1.03
Biological activity of lenalidomide and its underlying therapeutic effects in multiple myeloma. Adv Hematol (2012) 1.00
European perspective on multiple myeloma treatment strategies: update following recent congresses. Oncologist (2012) 0.98
Guidelines on the diagnosis and management of multiple myeloma treatment: Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular Project guidelines: Associação Médica Brasileira - 2012. Rev Bras Hematol Hemoter (2013) 0.98
Total cost comparison in relapsed/refractory multiple myeloma. J Med Econ (2013) 0.96
Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. Blood (2015) 0.95
Trial Watch: Lenalidomide-based immunochemotherapy. Oncoimmunology (2013) 0.94
A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial. J Hematol Oncol (2013) 0.92
Future agents and treatment directions in multiple myeloma. Expert Rev Hematol (2013) 0.92
In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone. Leukemia (2014) 0.92
Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma. Leukemia (2011) 0.90
Estimating the Costs of Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma: A Model Framework. Am Health Drug Benefits (2015) 0.88
Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European, multicenter cohort study. Support Care Cancer (2014) 0.88
Review of health-related quality of life data in multiple myeloma patients treated with novel agents. Leukemia (2013) 0.88
Novel agents and new therapeutic approaches for treatment of multiple myeloma. World J Methodol (2014) 0.86
Combination with a defucosylated anti-HM1.24 monoclonal antibody plus lenalidomide induces marked ADCC against myeloma cells and their progenitors. PLoS One (2013) 0.84
Lenalidomide for the treatment of relapsed and refractory multiple myeloma. Cancer Manag Res (2012) 0.84
Treatment of relapsed and refractory multiple myeloma. Haematologica (2016) 0.83
Neuropathic cancer pain: What we are dealing with? How to manage it? Onco Targets Ther (2014) 0.83
Lenalidomide at therapeutic and supratherapeutic doses does not prolong QTc intervals in the thorough QTc study conducted in healthy men. Basic Clin Pharmacol Toxicol (2013) 0.83
Expanding role of lenalidomide in hematologic malignancies. Cancer Manag Res (2015) 0.83
Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide. Haematologica (2015) 0.83
Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma. Blood (2016) 0.82
Current therapeutic strategies for multiple myeloma. Int J Clin Oncol (2015) 0.81
Use of lenalidomide in the management of relapsed or refractory multiple myeloma: expert recommendations in Korea. Blood Res (2015) 0.79
Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients ≥65 years old with relapsed or refractory multiple myeloma. Int J Hematol (2012) 0.78
Longitudinal analysis of patient-reported symptoms post-autologous stem cell transplant and their relationship to inflammation in patients with multiple myeloma. Leuk Lymphoma (2014) 0.78
American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. Biol Blood Marrow Transplant (2015) 0.78
Economic evaluation of therapies for patients suffering from relapsed-refractory multiple myeloma in Greece. Cancer Manag Res (2013) 0.78
Bortezomib-based vs non-bortezomib-based post-transplantation treatment in multiple myeloma patients: a systematic review and meta-analysis of Phase III randomized controlled trials. Onco Targets Ther (2015) 0.77
Lenalidomide in multiple myeloma-a practice guideline. Curr Oncol (2013) 0.77
Time-dependent endpoints as predictors of overall survival in multiple myeloma. BMC Cancer (2013) 0.77
Lenalidomide maintenance in myeloma. Nat Rev Clin Oncol (2012) 0.77
Safety and efficacy of lenalidomide in relapsed or refractory multiple myeloma. Clin Med Insights Oncol (2011) 0.76
Carfilzomib alters the HLA-presented peptidome of myeloma cells and impairs presentation of peptides with aromatic C-termini. Blood Cancer J (2016) 0.75
Efficacy and Safety of Lenalidomide in the Treatment of Multiple Myeloma: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Chin Med J (Engl) (2015) 0.75
Novel treatment strategy with autologous activated and expanded natural killer cells plus anti-myeloma drugs for multiple myeloma. Oncoimmunology (2016) 0.75
A case of refractory multiple myeloma with proliferation of large granular lymphocytes by lenalidomide treatment and its association with clinical efficacy. Mol Clin Oncol (2016) 0.75
Lenalidomide in the treatment of young patients with multiple myeloma: from induction to consolidation/maintenance therapy. Adv Hematol (2012) 0.75
Efficacy of dose-reduced lenalidomide in patients with refractory or recurrent multiple myeloma. Ger Med Sci (2011) 0.75
The interaction between oral melphalan and gastric antisecretory drugs: Impact on clinical efficacy and toxicity. Mol Clin Oncol (2015) 0.75
The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective. Adv Ther (2016) 0.75
The Diagnosis and Treatment of Multiple Myeloma. Dtsch Arztebl Int (2016) 0.75
Long-term use of lenalidomide and low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: MM-024 Extended Access Program. BMC Cancer (2016) 0.75
Secondary primary malignancies during the lenalidomide-dexamethasone regimen in relapsed/refractory multiple myeloma patients. Cancer Med (2016) 0.75
Clinical utility and patient consideration in the use of lenalidomide for multiple myeloma in Chinese patients. Onco Targets Ther (2015) 0.75
The potential of ixazomib, a second-generation proteasome inhibitor, in the treatment of multiple myeloma. Ther Adv Hematol (2017) 0.75
Use of direct oral anticoagulants in patients on immunomodulatory agents. J Thromb Thrombolysis (2017) 0.75
Combination of lenalidomide and low-dose dexamethasone therapy promotes the anticoagulant activity of warfarin in patients with immunoglobulin light-chain amyloidosis. Oncol Lett (2017) 0.75
High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet (1998) 21.52
International uniform response criteria for multiple myeloma. Leukemia (2006) 17.78
Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell (1994) 13.76
MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol Cell (1998) 8.73
Saturated molecular map of the rice genome based on an interspecific backcross population. Genetics (1994) 6.22
Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med (1996) 5.87
Requirement for Ku80 in growth and immunoglobulin V(D)J recombination. Nature (1996) 5.80
A new bacteriophage P1-derived vector for the propagation of large human DNA fragments. Nat Genet (1994) 5.34
Positive regulatory interactions of the HIS4 gene of Saccharomyces cerevisiae. Mol Cell Biol (1984) 5.08
Primary structure of two COOH-terminal hexapeptides from rabbit muscle aldolase: a difference in the structure of the alpha and beta subunits. Biochem Biophys Res Commun (1970) 4.68
Cloning of the essential myotonic dystrophy region and mapping of the putative defect. Nature (1992) 4.45
Multiple pathways cooperate in the suppression of genome instability in Saccharomyces cerevisiae. Nature (2001) 3.77
The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia (2008) 3.69
Polymerase chain reaction detection of 8 putative periodontal pathogens in subgingival plaque of gingivitis and advanced periodontitis lesions. Oral Microbiol Immunol (1996) 3.65
Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med (1996) 3.64
Characterization of the structure and function of a new mitogen-activated protein kinase (p38beta). J Biol Chem (1996) 3.63
SGS1, the Saccharomyces cerevisiae homologue of BLM and WRN, suppresses genome instability and homeologous recombination. Nat Genet (2001) 3.60
A 5-bp deletion in ELOVL4 is associated with two related forms of autosomal dominant macular dystrophy. Nat Genet (2001) 3.52
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol (2004) 3.49
Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med (1996) 3.41
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia (2008) 3.41
Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol (2004) 3.37
Deficient cerebellar long-term depression and impaired motor learning in mGluR1 mutant mice. Cell (1994) 3.35
The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kappaB that blocks TNFalpha-induced apoptosis. Genes Dev (1999) 3.25
Inter-RNA interaction of phage phi29 pRNA to form a hexameric complex for viral DNA transportation. Mol Cell (1998) 3.21
Preserved acute pain and reduced neuropathic pain in mice lacking PKCgamma. Science (1997) 2.98
Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol (1998) 2.96
The effects of mercaptoethanol and of peritoneal macrophages on the antibody-forming capacity of nonadherent mouse spleen cells in vitro. J Exp Med (1972) 2.95
Evidence for an important role of WRKY DNA binding proteins in the regulation of NPR1 gene expression. Plant Cell (2001) 2.90
The management of unicentric and multicentric Castleman's disease: a report of 16 cases and a review of the literature. Cancer (1999) 2.90
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia (2007) 2.76
Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol (2001) 2.71
Pregnancy after human oocyte cryopreservation. Lancet (1986) 2.67
Cellular Fractionation of Chlamydomonas reinhardii with Emphasis on the Isolation of the Chloroplast. Plant Physiol (1983) 2.64
Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol (1998) 2.60
Transposon diversity in Arabidopsis thaliana. Proc Natl Acad Sci U S A (2000) 2.57
Chorea-ballismus with nonketotic hyperglycemia in primary diabetes mellitus. AJNR Am J Neuroradiol (1996) 2.54
High-dose cytarabine (24 g/m2) in combination with idarubicin (HiDAC-3) results in high first-cycle response with limited gastrointestinal toxicity in adult acute myeloid leukaemia. Intern Med J (2013) 2.53
Mch3, a novel human apoptotic cysteine protease highly related to CPP32. Cancer Res (1995) 2.47
Genetic analysis of yeast RPA1 reveals its multiple functions in DNA metabolism. Genetics (1998) 2.37
Establishment, maintenance and description of cell lines from the tick Ixodes scapularis. J Parasitol (1994) 2.36
Fire and flood management of coastal swamp enabled first rice paddy cultivation in east China. Nature (2007) 2.36
Characterization of labeled ribonucleic acid from tissue grown on 14C-containing cytokinins. J Biol Chem (1967) 2.30
Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol (1999) 2.29
HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway. J Biol Chem (2000) 2.29
Conspecificity of the ticks Ixodes scapularis and I. dammini (Acari: Ixodidae). J Med Entomol (1993) 2.28
Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients. Leukemia (2007) 2.28
International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma. Leukemia (2009) 2.28
Detection and incidence of specific species of spoilage bacteria on fish. II. Relative incidence of Pseudomonas putrefaciens and fluorescent pseudomonads on haddock fillets. Appl Microbiol (1968) 2.27
Targeted cytoplasmic irradiation with alpha particles induces mutations in mammalian cells. Proc Natl Acad Sci U S A (1999) 2.27
Topical or oral ibuprofen for chronic knee pain in older people. The TOIB study. Health Technol Assess (2008) 2.24
Marginal costs and benefits. BMJ (1996) 2.22
Subsecond induction of alpha4 integrin clustering by immobilized chemokines stimulates leukocyte tethering and rolling on endothelial vascular cell adhesion molecule 1 under flow conditions. J Exp Med (2000) 2.21
Coregulation of type 12 M protein and streptococcal C5a peptidase genes in group A streptococci: evidence for a virulence regulon controlled by the virR locus. J Bacteriol (1990) 2.16
An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology (1999) 2.16
Photosynthetic Properties of Chloroplasts from Chlamydomonas reinhardii. Plant Physiol (1983) 2.15
Modified hippocampal long-term potentiation in PKC gamma-mutant mice. Cell (1993) 2.14
Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B--a prospective cohort study with paired transient elastography examinations. Aliment Pharmacol Ther (2014) 2.11
Brain: gadolinium-enhanced fast fluid-attenuated inversion-recovery MR imaging. Radiology (1999) 2.07
Lamictal (lamotrigine) monotherapy for typical absence seizures in children. Epilepsia (1999) 2.03
How far does screening women for domestic (partner) violence in different health-care settings meet criteria for a screening programme? Systematic reviews of nine UK National Screening Committee criteria. Health Technol Assess (2009) 2.03
A minK-HERG complex regulates the cardiac potassium current I(Kr). Nature (1997) 2.03
Stroke physician versus stroke neurologist: can anyone thrombolyse? Intern Med J (2015) 2.02
Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia (2009) 1.97
Higher doses of CD34+ peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation. Leukemia (2003) 1.96
Early fixation of an optimal genetic code. Mol Biol Evol (2000) 1.94
Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition. Gene Ther (2008) 1.94
Genetic immunization against herpes simplex virus. Protection is mediated by CD4+ T lymphocytes. J Immunol (1995) 1.94
Activation of mitogen-activated protein kinase pathways induces antioxidant response element-mediated gene expression via a Nrf2-dependent mechanism. J Biol Chem (2000) 1.90
A refined solution structure of hen lysozyme determined using residual dipolar coupling data. Protein Sci (2001) 1.88
Intermittent vascular exclusion of the liver (without vena cava clamping) during major hepatectomy. Br J Surg (1995) 1.88
Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia (2007) 1.86
PKC gamma mutant mice exhibit mild deficits in spatial and contextual learning. Cell (1993) 1.84
Enrichment of cis-regulatory gene expression SNPs and methylation quantitative trait loci among bipolar disorder susceptibility variants. Mol Psychiatry (2012) 1.84
Mesenchymal stem cell-based angiopoietin-1 gene therapy for acute lung injury induced by lipopolysaccharide in mice. J Pathol (2008) 1.84
Whisker-related neuronal patterns fail to develop in the trigeminal brainstem nuclei of NMDAR1 knockout mice. Cell (1994) 1.82
Recommended guidelines for the management of autologous and allogeneic bone marrow transplantation. A report from the Eastern Cooperative Oncology Group (ECOG) Ann Intern Med (1994) 1.81
Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia (2006) 1.79
Structural and dynamical properties of a denatured protein. Heteronuclear 3D NMR experiments and theoretical simulations of lysozyme in 8 M urea. Biochemistry (1997) 1.75
Impact of acid and pepsin on human esophageal prostaglandins. Am J Gastroenterol (1994) 1.75
High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol (1997) 1.75
Evaluation of four automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Clin Chem (2000) 1.74
Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Société Française de Greffe de Moelle. J Clin Oncol (2000) 1.73
Characterization of sodium channel alpha- and beta-subunits in rat and mouse cardiac myocytes. Circulation (2001) 1.73
No safe haven. II: The effects of violence exposure on urban youth. J Am Acad Child Adolesc Psychiatry (1999) 1.71
Roles of nuclear factor kappaB in neuronal survival and plasticity. J Neurochem (2000) 1.70
Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia (2011) 1.70
Human infection with avian influenza A(H7N9) virus re-emerges in China in winter 2013. Euro Surveill (2013) 1.68
Deficient cerebellar long-term depression, impaired eyeblink conditioning, and normal motor coordination in GFAP mutant mice. Neuron (1996) 1.67
Identification of new microRNA genes and aberrant microRNA profiles in childhood acute lymphoblastic leukemia. Leukemia (2008) 1.67
Adjuvant rituximab causes prolonged hypogammaglobulinaemia following autologous stem cell transplant for non-Hodgkin's lymphoma. Bone Marrow Transplant (2006) 1.67
Localization of a gene for myoclonus-dystonia to chromosome 7q21-q31. Ann Neurol (1999) 1.67
Orientation of prophage Mu. Virology (1973) 1.67
Is the dementia rate increasing in Beijing? Prevalence and incidence of dementia 10 years later in an urban elderly population. Acta Psychiatr Scand (2007) 1.65
The molecular basis of nuclear genetic code change in ciliates. Curr Biol (2001) 1.65
Cytogenetic findings in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. Chromosomal abnormalities are associated with the polymorphous subtype and an aggressive clinical course. Am J Clin Pathol (2001) 1.65
Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial. Br J Cancer (2013) 1.65